|
|
Phase II Study of Bortezomib in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
MSKCC-03101 NCI-6003, NCT00074009, 6003
|
|
|
Objectives Primary - Determine the efficacy of bortezomib in patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Secondary - Determine the toxicity of this drug in these patients.
- Determine possible predictors of response to this drug, using pretreatment tumor immunohistochemistry, in these patients.
Entry Criteria Disease Characteristics:
- Histologically or cytologically confirmed unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
- Siewert’s class II or III disease
- Measurable disease
- At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- No history of known or active brain metastases or primary brain tumors
Prior/Concurrent Therapy:
Biologic therapy - More than 3 weeks since prior immunotherapy
-
No concurrent biological or immunological agents
Chemotherapy - No more than 1 prior chemotherapy regimen (including adjuvant chemotherapy)
-
More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- No concurrent chemotherapy
Endocrine therapy Radiotherapy - More than 3 weeks since prior radiotherapy
- No concurrent radiotherapy
Surgery Other - Recovered from all prior therapy
- No other concurrent investigational agents
- No other concurrent anticancer agent or therapy
Patient Characteristics:
Age Performance status - Karnofsky 60-100%
OR -
ECOG 0-2
Life expectancy Hematopoietic - WBC at least 3,000/mm3
- Absolute neutrophil count at least 1,000/mm3
-
Platelet count at least 100,000/mm3
Hepatic - Bilirubin no greater than 1.5 mg/dL
-
AST and ALT no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
Renal - Creatinine no greater than 1.5 mg/dL
Cardiovascular - No prior cerebrovascular event
- No prior orthostatic hypotension
- No myocardial infarction within the past 6 months
-
No peripheral vascular disease requiring surgical management
-
No evidence of acute ischemia or significant conduction abnormality by EKG
Other - Not pregnant or nursing
-
Negative pregnancy test
- Fertile patients must use effective contraception during and for at least 2 months after study participation
-
No evidence of peripheral neuropathy
-
No prior allergic reaction attributed to compounds of similar chemical or biological composition to bortezomib
-
No other malignancy within the past 3 years except basal cell skin cancer, carcinoma in situ of the cervix, or adequately treated nonmetastatic prostate cancer
-
No ongoing or active infection
- No psychiatric illness or social situation that would preclude study participation
-
No other concurrent uncontrolled illness that would preclude study participation
- No other medical condition or reason that would preclude study participation
Expected Enrollment A total of 15-33 patients will be accrued for this study within 5-12 months. Outline This is an open-label, nonrandomized, multicenter study.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year.
Trial Contact Information
Trial Lead Organizations Memorial Sloan-Kettering Cancer Center | | | Manish Shah, MD, Principal investigator | | Ph: 212-639-3113; 800-525-2225 |
| | Gary K. Schwartz, MD, Principal investigator | | Ph: 212-639-8324; 800-525-2225 |
| |
Registry Information | | Official Title | | A Multicenter, Open-Label, Two-Stage, Phase II Study Of PS-341 (LDP-341, NSC # 681239) In Patients With Unresectable Or Metastatic Gastric Adenocarcinoma | | Trial Start Date | | 2003-10-16 | | Registered in ClinicalTrials.gov | | NCT00074009 | | Date Submitted to PDQ | | 2003-10-21 | | Information Last Verified | | 2005-04-06 | | NCI Grant/Contract Number | | P30-CA08748, N01-CM17105 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|